Harmony Biosciences Reports Record Q4 Net Revenue and Ambitious 2025 Pipeline
Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) announced on February 25, 2025 its financial results for the quarter and full year ended December 31, 2024, marking a milestone with record net revenue figures. In its latest SEC filing on Form 8-K, the company detailed that Q4 2024 net revenue reached $201.3 million – the highest level […]
Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) announced on February 25, 2025 its financial results for the quarter and full year ended December 31, 2024, marking a milestone with record net revenue figures. In its latest SEC filing on Form 8-K, the company detailed that Q4 2024 net revenue reached $201.3 million – the highest level […]
